Publicly-traded company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) had a closing price of $28.10 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $17.29, this means that the stock is overpriced by -62.52%. In the past 52 weeks the company’s stock price has moved within the range of $4.01 to $15.63.
This particular stock’s 5-day moving average is 16.99, its 20-day moving average is 13.68 and its 100-day moving average is 9.54. Constellation Pharmaceuticals Inc. (CNST) currently has 25.24M shares outstanding, which means that its market capitalization is $709.24M.
The Details: Constellation Pharmaceuticals Inc. (CNST) Financial Health
We can also see what the current Return on Assets is for the company, which is a percentage that lets us know how well it is utilizing its net assets to turn a profit. The lower the percentage, the worse the company is making use of its assets. At the moment, Constellation Pharmaceuticals Inc. Return on Assets is -61.90%.
What Does Wall Street Say about Company?
When investors are considering buying a new stock, they often want to know the general Wall Street consensus on the company – by checking out the average analyst rating, for instance. At the moment, the average analyst rating for CNST is Buy. Out of 7 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 1 rated it an overweight, 0 rated it hold, and 6 rated it a Buy.
Understanding Profitability at Constellation Pharmaceuticals Inc. (CNST)
Checking out a public company’s Earnings per Share (EPS) is a smart way of assessing its profitability. In the most recent financial results released by Constellation Pharmaceuticals Inc., for the quarter ending on 09/2019, the company posted EPS of -0.81. The average estimate of Wall Street analysts had projected -0.80.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.83, compared to -0.81 reported in the same quarter last year.